To further investigate the involvement of mTOR/NF-κB/IL-1β pathway in the antidepressant effects of COS, the pharmacological methods were applied that COS treatment (20 mg/kg, i.p.)and infusion of vehicle or MHY1485 (10 μM, 1 μL per side) into DG of control or CRS-exposed mice (Fig. 6a). This evidence concerns the gene NFKB1 and congenital rubella syndrome.